Youssef Bennani

As Chief Scientific Officer, Dr. Youssef Bennani is taking overall responsibility for the scientific direction of the organization and assisting Venture Partners and the Program Development and Partnership teams focus their efforts around areas of interest.

Dr. Youssef Bennani is currently Chairman of the Board of Domain Therapeutics (France & Canada), and is an independent Board member of Bellus Health (TSX:BLU). He has over 25 years experience in pharmaceutical R&D leadership and management serving most recently as Site Head and Vice President of R&D at Vertex Pharmaceuticals Canada Inc. Prior to this position, Dr. Bennani spent several years as Vice President Drug Innovation at Vertex’s Headquarters (Boston – MA). He has also held various positions of increasing responsibility in pharmaceutical R&D at Ligand Pharmaceuticals, Abbott Laboratories (now Abbvie) and Athersys. His experience spans multiple therapeutic areas including oncology, neurology, infection, inflammation and renal diseases.

Dr. Bennani has studied in chemistry (PhD, Université de Montréal), business (MBA, LFGSM – Chicago) and corporate governance (ICD.D, McGill-Rotman Schools of Business).